Conclusion - adverse effects of Hormonal contraception
Large investiments are being made focalized on prevention of unwilling pregnancy and sexually transmitted disease in several countries, but the relevance of the problem requires the interest at international political levels. Contraception is a crucial human right for its role in health, development and quality of life. In spite of shortcomings of currently available male contraception, 1/3 of the couples that use contraception worldwide rely on male methods, suggesting that the development of a safe, effective, reversible and affordable contraceptive method for men would meet a critical need(16). Because rates of unintended pregnancy, abortion and unintended birth are very high among adult women in the United States, it is important to identify interventions that can increase contraceptive use in the population, such as vaccines. Currently, vaccines are still experimental and until now were tested in animal and in women of developing countries(17,18). A research plan that rigorously assesses the impact of different approaches to increasing contraceptive use among adult and young women, should be an integral part of any long-term effort to prevent unintended pregnancy(19)
Adverse Effects of Hormonal contraception
- Moderate adverse effects
- Cardiovascular Effects
- Other Effects
- Cancer Risks
- Contraception in women HIV infected
- Mild Adverse effects
- - Irregular Bleeding Pattern
- - Ovarian cysts
- - Depression
- - Low Libido
- - Vaginal Infections
- New Perspectives immunocontraception
- - PMRS and PAS
- Contraceptive counseling
- Conclusion
—
Rosa Sabatini and Raffele Cagiano
Department of Obstetrics and Gynecology
Department of Pharmacology General Hospital Policlinico-University of Bari, Italy
—
REFERENCES
- Erkkola R. (2006). Recent advances in contraception. Minerva Ginecol, 58(4), 295-305.
- Grimes D.A. (2003). Unsafe abortion: the silent scourge. Br.Med.Bull, 67, 99-113.
- Okonofua F.(2006). Abortion and maternal mortality in the developing world. J. Obstet. Gynaecol. Can, 28(11),974-9.[4] Fawcus,S.R. (2008). Maternal mortality and unsafe abortion. Best Pract. Res. Clin. Obstet. Gynaecol, 22(3), 533-48.
- Economidis M.A., Mishell D.R. Jr. (2005). Pharmacological female contraception: an overview of past and future use. Expert Opin. Invastig. Drugs, 14(4), 449-56.
- Benagiano G., Bastianelli C., Farris M. Contraception today. Ann. N.Y.Acad. Sci.2006; 1092; 1-32.
- Cheung E., Free, C. (2005). Factors influencing young women’s decision-making regarding hormonal contraceptives: a qualitative study. Contraception, 71, 426-31.
- Seifert-Klauss V., Kaemmerer H., Brunner B., Schneider K.T., Hess, J. (2000). Contraception in patients with congenital heart defects. Z.Kardiol, 89(7), 606-11.
- Teal S.B., Ginosar D.M. (2007). Contraception for women with chronic medical conditions. Obstet. Gynecol. Clin. North Am,34(1), 113- 26.
- Tong H.K., Fai G.L., Ann L.T., Hock O.B. (1981). Budd-Chiari syndrome and hepatic adenomas associated with oral contraceptives. A case report. Singapore Med. J, 22(3), 168-72.
- Shilling M.K., Zimmermann A., Radaelli C., Seiler C.A., Buchler M.W. (2000). Liver nodules resembling focal nodular hyperplasia after hepatic venous thrombosis. J.Hepatol, 33(4),673-6.
- Jungers P., Dougados M., Pelissier C., Kuttenn F., Tron F., Pertuiset N., Bach J.F. (1982). Effect of hormonal contraception on the course of lupus nephropathy. Nouv. Presse Med, 11(51), 3765-8.
- Lakasing L., Khamashta M. (2001). Contraceptive practices in women with systemic lupus erythematous and/or antiphospholipid syndrome: what advice should we be giving? J.Fam. Plann. Reprod. Health Care, 27(1), 7-12.
- Chengalvala M.V., Meade E.H. Jr, Cottom J.E., Hoffman W.H., Shanno L.K., Wu M.M., Kopf G.S., Shen E.S.(2006). Regulation of female fertility and identification of future contraceptive targets. Curr. Pharm. Des,12(30), 3915-28.
- Chabbert-Buffet N., Meduri, G., Bouchard P., Spitz I.M. (2005). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update, 11(3), 293-307.
- Costantino A., Cerpolini S., Perrone A.M., Ghi T., Pelusi C., Pelusi G., Meriggiola M.C. (2007). Current status and future perspectives in male contraception. Minerva Ginecol, 59(3), 299-310.
- Suri A. (2004). Sperm specific proteins-potential candidate molecules for fertility control. Reprod. Biol. Endocrinol, 2,10.
- Chamley L.W., Clarke G.N. (2007).Antisperm antibodies and conception. Semin. Immunopathol, 29 (2),169-84
- Kirby D. (2008). The impact of programs to increase contraceptive use among adult women:a review of experimental and quasi-experimental studies. Perspect Sex Reprod Health. Mar, 40(1),34-41.